KIT as a therapeutic target for non-oncological diseases.

Abstract:

:KIT is a receptor tyrosine kinase that after binding to its ligand stem cell factor activates signaling cascades linked to biological processes such as proliferation, differentiation, migration and cell survival. Based on studies performed on SCF and/or KIT mutant animals that presented anemia, sterility, and/or pigmentation disorders, KIT signaling was mainly considered to be involved in the regulation of hematopoiesis, gametogenesis, and melanogenesis. More recently, novel animal models and ameliorated cellular and molecular techniques have led to the discovery of a widen repertoire of tissue compartments and functions that are being modulated by KIT. This is the case for the lung, heart, nervous system, gastrointestinal tract, pancreas, kidney, liver, and bone. For this reason, the tyrosine kinase inhibitors that were originally developed for the treatment of hemato-oncological diseases are being currently investigated for the treatment of non-oncological disorders such as asthma, rheumatoid arthritis, and alzheimer's disease, among others. The beneficial effects of some of these tyrosine kinase inhibitors have been proven to depend on KIT inhibition. This review will focus on KIT expression and regulation in healthy and pathologic conditions other than cancer. Moreover, advances in the development of anti-KIT therapies, including tyrosine kinase inhibitors, and their application will be discussed.

journal_name

Pharmacol Ther

authors

Martinez-Anton A,Gras D,Bourdin A,Dubreuil P,Chanez P

doi

10.1016/j.pharmthera.2018.12.008

subject

Has Abstract

pub_date

2019-05-01 00:00:00

pages

11-37

eissn

0163-7258

issn

1879-016X

pii

S0163-7258(18)30230-4

journal_volume

197

pub_type

杂志文章,评审
  • RNA interference: from gene silencing to gene-specific therapeutics.

    abstract::In the past 4 years, RNA interference (RNAi) has become widely used as an experimental tool to analyse the function of mammalian genes, both in vitro and in vivo. By harnessing an evolutionary conserved endogenous biological pathway, first identified in plants and lower organisms, double-stranded RNA (dsRNA) reagents ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2005.03.004

    authors: Leung RK,Whittaker PA

    更新日期:2005-08-01 00:00:00

  • Pharmacological control of gastric acid secretion for the treatment of acid-related peptic disease: past, present, and future.

    abstract::Pharmacological agents, such as histamine H(2) receptor antagonists and acid pump inhibitors, are now the most frequently used treatment for such acid-related diseases as gastroduodenal ulcers and reflux esophagitis. Based on increased understanding of the precise mechanisms of gastric acid secretion at the level of r...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(03)00015-9

    authors: Aihara T,Nakamura E,Amagase K,Tomita K,Fujishita T,Furutani K,Okabe S

    更新日期:2003-04-01 00:00:00

  • Advances in small molecules promoting neurotrophic function.

    abstract::Nerve growth factor (NGF) and other members of the neurotrophin family are critical for the survival and differentiation of neurons and have been implicated in the pathophysiology of numerous disease states. Although the therapeutic potential of neurotrophins has generated much excitement over the past decade, inconve...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2007.03.005

    authors: Price RD,Milne SA,Sharkey J,Matsuoka N

    更新日期:2007-08-01 00:00:00

  • O-GlcNAc and the cardiovascular system.

    abstract::The cardiovascular system is capable of robust changes in response to physiologic and pathologic stimuli through intricate signaling mechanisms. The area of metabolism has witnessed a veritable renaissance in the cardiovascular system. In particular, the post-translational β-O-linkage of N-acetylglucosamine (O-GlcNAc)...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2013.11.005

    authors: Dassanayaka S,Jones SP

    更新日期:2014-04-01 00:00:00

  • The IL-33/ST2 pathway--A new therapeutic target in cardiovascular disease.

    abstract::Numerous pro-inflammatory cytokines have been implicated in the pathogenesis of several cardiovascular diseases. Interleukin (IL)-33 is a new member of the IL-1 family of cytokines that promotes Th2 type immune responses by signaling through the ST2L and IL-1RAcP dimeric receptor complex. Furthermore, the biological e...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2011.02.005

    authors: Miller AM,Liew FY

    更新日期:2011-08-01 00:00:00

  • Role of pharmacotherapy in cardiac ion channelopathies.

    abstract::In the last decade, there have been considerable advances in the understanding of the pathophysiology of malignant ventricular tachyarrhythmias (VT) and sudden cardiac death (SCD). Over 80% of SCD occurs in patients with organic heart disease. However, approximately 10%-15% of SCD occurs in the presence of structurall...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2015.09.002

    authors: El-Sherif N,Boutjdir M

    更新日期:2015-11-01 00:00:00

  • Molecular genetics of the renin-angiotensin system: implications for angiotensin II receptor blockade.

    abstract::Angiotensin II (Ang II) is the main effector hormone of the renin-angiotensin system (RAS). The pathogenesis of many cardiovascular diseases, including heart failure and hypertension, appear to be related to Ang II production. The generation of Ang II involves angiotensin-converting enzyme (ACE) in circulating and tis...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(97)00021-1

    authors: Davis GK,Roberts DH

    更新日期:1997-01-01 00:00:00

  • The role of the renin-angiotensin system in thoracic aortic aneurysms: clinical implications.

    abstract::Thoracic aortic aneurysms (TAAs) are a potential life-threatening disease with limited pharmacological treatment options. Current treatment options are aimed at lowering aortic hemodynamic stress, predominantly with β-adrenoceptor blockers. Increasing evidence supports a role for the renin-angiotensin system (RAS) in ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2011.04.002

    authors: Moltzer E,Essers J,van Esch JH,Roos-Hesselink JW,Danser AH

    更新日期:2011-07-01 00:00:00

  • Gold nanoparticles, radiations and the immune system: Current insights into the physical mechanisms and the biological interactions of this new alliance towards cancer therapy.

    abstract::Considering both cancer's serious impact on public health and the side effects of cancer treatments, strategies towards targeted cancer therapy have lately gained considerable interest. Employment of gold nanoparticles (GNPs), in combination with ionizing and non-ionizing radiations, has been shown to improve the effe...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2017.03.006

    authors: Dimitriou NM,Tsekenis G,Balanikas EC,Pavlopoulou A,Mitsiogianni M,Mantso T,Pashos G,Boudouvis AG,Lykakis IN,Tsigaridas G,Panayiotidis MI,Yannopapas V,Georgakilas AG

    更新日期:2017-10-01 00:00:00

  • Chemical complementation: a definitive phenotypic strategy for identifying small molecule inhibitors of elusive cellular targets.

    abstract::Forward Pharmacology seeks to identify small or large molecules that modulate a normal or abnormal biological process in living cells or whole organisms and historically has been responsible for the discovery of many clinically used drugs. Forward Pharmacology approaches have become particularly attractive because adv...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2005.03.002

    authors: Vogt A,Lazo JS

    更新日期:2005-08-01 00:00:00

  • Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease.

    abstract::Infection or sterile inflammation triggers site-specific attraction of leukocytes. Leukocyte recruitment is a process comprising several steps orchestrated by adhesion molecules, chemokines, cytokines and endogenous regulatory molecules. Distinct adhesive interactions between endothelial cells and leukocytes and signa...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2014.11.008

    authors: Mitroulis I,Alexaki VI,Kourtzelis I,Ziogas A,Hajishengallis G,Chavakis T

    更新日期:2015-03-01 00:00:00

  • Pokeweed antiviral protein: ribosome inactivation and therapeutic applications.

    abstract::Pokeweed antiviral protein (PAP) is a ribosome-inactivating protein (RIP) that inactivates ribosomes by the removal of a single adenine from ribosomal RNA. The studies summarized in our review concern the nature and application of this novel therapeutic agent. We describe how researchers continue to elucidate the stru...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(92)90053-3

    authors: Irvin JD,Uckun FM

    更新日期:1992-01-01 00:00:00

  • Glycine transporter inhibitors as a novel drug discovery strategy for neuropathic pain.

    abstract::Injury to peripheral or spinal nerves following either trauma or disease has several consequences including the development of neuropathic pain. This syndrome is often refractory against conventional analgesics; and thus, novel medicaments are desired for its treatment. Recent studies have emphasized that dysfunction ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.pharmthera.2009.03.018

    authors: Dohi T,Morita K,Kitayama T,Motoyama N,Morioka N

    更新日期:2009-07-01 00:00:00

  • Binge-eating disorder: Clinical and therapeutic advances.

    abstract::Binge-eating disorder (BED) is the most prevalent eating disorder with estimates of 2-5% of the general adult population. Nonetheless, its pathophysiology is poorly understood. Furthermore, there exist few therapeutic options for its effective treatment. Here we review the current state of binge-eating neurobiology an...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2017.08.002

    authors: Hutson PH,Balodis IM,Potenza MN

    更新日期:2018-02-01 00:00:00

  • Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment.

    abstract::Relationship between inflammation and cancer is now well-established and represents a paradigm that our immune response does not necessarily serves solely to protect us from infections and cancer. Many specific mechanisms that link chronic inflammation to cancer promotion and metastasis have been uncovered in the rece...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2016.09.011

    authors: Atretkhany KN,Drutskaya MS,Nedospasov SA,Grivennikov SI,Kuprash DV

    更新日期:2016-12-01 00:00:00

  • Changes in deoxynucleoside triphosphate pools induced by inhibitors and modulators of ribonucleotide reductase.

    abstract::Changes in dNTP pools have been studied by a number of investigators, in a wide range of cell types. The in vitro pertubations in dNTP pool levels induced, in particular, by deoxynucleosides which act as allosteric modulators, are not totally consistent with current 'in vitro models' of ribonucleotide reductase functi...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(85)90046-4

    authors: Fox RM

    更新日期:1985-01-01 00:00:00

  • Challenges and achievements in the therapeutic modulation of aquaporin functionality.

    abstract::Aquaporin (AQP) water and solute channels have basic physiological functions throughout the human body. AQP-facilitated water permeability across cell membranes is required for rapid reabsorption of water from pre-urine in the kidneys and for sustained near isosmolar water fluxes e.g. in the brain, eyes, inner ear, an...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2015.08.002

    authors: Beitz E,Golldack A,Rothert M,von Bülow J

    更新日期:2015-11-01 00:00:00

  • Delta opioid receptors in brain function and diseases.

    abstract::Evidence that the delta opioid receptor (DOR) is an attractive target for the treatment of brain disorders has strengthened in recent years. This receptor is broadly expressed in the brain, binds endogenous opioid peptides, and shows as functional profile highly distinct from those of mu and kappa opioid receptors. Ou...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2013.06.003

    authors: Chu Sin Chung P,Kieffer BL

    更新日期:2013-10-01 00:00:00

  • Nicotinic acetylcholine receptors: from basic science to therapeutics.

    abstract::Substantial progress in the identification of genes encoding for a large number of proteins responsible for various aspects of neurotransmitter release, postsynaptic detection and downstream signaling, has advanced our understanding of the mechanisms by which neurons communicate and interact. Nicotinic acetylcholine r...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2012.08.012

    authors: Hurst R,Rollema H,Bertrand D

    更新日期:2013-01-01 00:00:00

  • Matrix reloaded: CCN, tenascin and SIBLING group of matricellular proteins in orchestrating cancer hallmark capabilities.

    abstract::Matricellular proteins (MCPs) are the non-structural extracellular matrix (ECM) proteins with various regulatory functions. MCPs are critical regulators of ECM homeostasis and are often found dysregulated in various malignancies. They interact with various proteins like ECM structural proteins, integrins, growth facto...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2016.09.002

    authors: Thakur R,Mishra DP

    更新日期:2016-12-01 00:00:00

  • Monoclonal antibodies as probes of structure, function and isoenzyme forms of the type II regulatory subunit of cyclic AMP-dependent protein kinase.

    abstract::We have attempted to review studies which have utilized monoclonal antibodies in the analysis of various aspects of type II cAMP-dependent protein kinase. It is readily apparent that the monoclonal antibodies directed against RII can be used in a number of ways to assess the structure and function of this protein. Mon...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(85)90059-2

    authors: Mumby MC,Weldon SL,Scott CW,Taylor SS

    更新日期:1985-01-01 00:00:00

  • Structure-nongenomic neuroprotection relationship of estrogens and estrogen-derived compounds.

    abstract::Nongenomic estrogen signaling pathways involve extranuclear estrogen receptors or function independently from estrogen receptors. These pathways participate in neuroprotection elicited by the hormone. Additional nongenomic neuroprotective effects are attributable to antioxidant and antiinflammatory actions of estrogen...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2007.01.006

    authors: Prokai L,Simpkins JW

    更新日期:2007-04-01 00:00:00

  • Respiratory syncytial virus disease mechanisms implicated by human, animal model, and in vitro data facilitate vaccine strategies and new therapeutics.

    abstract::Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis, pneumonia, mechanical ventilation, and respiratory failure in infants in the US. No effective post-infection treatments are widely available, and currently there is no vaccine. RSV disease is the result of virus-induced airway damage and complex ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2006.04.008

    authors: Moore ML,Peebles RS Jr

    更新日期:2006-11-01 00:00:00

  • Contributions of cyclooxygenase-2 to neuroplasticity and neuropathology of the central nervous system.

    abstract::Cyclooxygenase (COX) enzymes, or prostaglandin-endoperoxide synthases (PTGS), are heme-containing bis-oxygenases that catalyze the first committed reaction in metabolism of arachidonic acid (AA) to the potent lipid mediators, prostanoids and thromboxanes. Two isozymes of COX enzymes (COX-1 and COX-2) have been identif...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2005.04.011

    authors: Hewett SJ,Bell SC,Hewett JA

    更新日期:2006-11-01 00:00:00

  • Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.

    abstract::Known treatments of type 2 diabetes mellitus have limitations such as weight gain, and hypoglycaemias. A new perspective is the use of incretin hormones and incretin enhancers. Incretins are defined as being responsible for the higher insulin release after an oral glucose load compared to an intravenous glucose load. ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2009.06.002

    authors: Verspohl EJ

    更新日期:2009-10-01 00:00:00

  • Contribution of metabotropic GABA(B) receptors to neuronal network construction.

    abstract::In the 1980s, Bowery and colleagues discovered the presence of a novel, bicuculline-resistant and baclofen-sensitive type of GABA receptor on peripheral nerve terminals, the GABA(B) receptor. Since this pioneering work, GABA(B) receptors have been identified in the Central Nervous System (CNS), where they provide an i...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2011.06.004

    authors: Gaiarsa JL,Kuczewski N,Porcher C

    更新日期:2011-11-01 00:00:00

  • Modulating microRNAs in cardiac surgery patients: Novel therapeutic opportunities?

    abstract::This review focuses on microRNAs (miRs) in cardiac surgery, where they are emerging as potential targets for therapeutic intervention as well as novel clinical biomarkers. Identification of the up/down-regulation of specific miRs in defined groups of cardiac surgery patients can lead to the development of novel strate...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2016.11.004

    authors: Biglino G,Caputo M,Rajakaruna C,Angelini G,van Rooij E,Emanueli C

    更新日期:2017-02-01 00:00:00

  • The sphingosine kinase-1/sphingosine-1-phosphate axis in cancer: Potential target for anticancer therapy.

    abstract::Sphingolipid metabolites, such as ceramide, sphingosine and sphingosine-1-phosphate (S1P), play many important roles in cellular activities. Ceramide and sphingosine inhibit cell proliferation and induce cell apoptosis while S1P has the opposite effect. Maintaining a metabolic balance of sphingolipids is essential for...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2018.10.011

    authors: Zheng X,Li W,Ren L,Liu J,Pang X,Chen X,Kang,Wang J,Du G

    更新日期:2019-03-01 00:00:00

  • Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing.

    abstract::Artemisinins are a unique class of antimalarial drugs with significant potential for drug repurposing for a wide range of diseases including cancer. Cancer is a leading cause of death globally and the majority of cancer related deaths occur in Low and Middle Income Countries (LMICs) where conventional treatment option...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107706

    authors: Augustin Y,Staines HM,Krishna S

    更新日期:2020-12-01 00:00:00

  • Cyclic nucleotide phosphodiesterases: New targets in the metabolic syndrome?

    abstract::Metabolic diseases have a tremendous impact on human morbidity and mortality. Numerous targets regulating adenosine monophosphate kinase (AMPK) have been identified for treating the metabolic syndrome (MetS), and many compounds are being used or developed to increase AMPK activity. In parallel, the cyclic nucleotide p...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107475

    authors: Lugnier C,Meyer A,Talha S,Geny B

    更新日期:2020-04-01 00:00:00